Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response

• DOI: 10.1007/s00392-022-02075-2
• Publication Date: 2022-08-22T13:06:12Z
• Authors: Angelika Costard-...; René Schramm; Bastian Fischer; Rasmus Rivinius; Raphael Bruno; Benjamin Müller; Armin Zittermann; Udo Boeken; Ralf Westenfeld; Cornelius Knabbe; Jan Gummert
• Keywords: Immunosuppression; Regimen; Antibody response; Humoral immunity

We report the results of a prospective study on immunogenicity 3rd dose BNT162b2 in thoracic organ recipients with no or minimal response following two-dose vaccination scheme.A total 243 transplant received homologue dose. Anti-SARS-CoV2-immunoglobulins (IgGs) were monitored immediately before (T1), 4 weeks (T2) as well 2 and months after Neutralizing antibody capacity (NAC) was determined at T2. To reveal predictors for detectable humoral response, patients divided into positive group (n = 129) based combined criteria IgGs NAC above defined cut-offs T2-and negative 114), both, beyond cut-offs.The induced 53% T2, 47% still non-responsive. Sero-positivity significantly stronger who presented weak, but already prior to booster when compared those T1. Multivariable analysis identified age > 55 years, period since transplantation < reduced glomerular filtration rate, triple immunosuppressive regimen, use tacrolimus mycophenolate independent risk factors lack response.Our data indicate that is linked type extent maintenance immunosuppression. The necessity cumulative regimen might individually be questioned possibly enhance chance an immune additional